Showing 708 results
-
Media Release /
-
Media Release /- New data from PARADIGM-HF shows LCZ696 cut incidence of sudden deaths, emergency room visits, hospitalizations, worsening symptoms and need for more intense treatment in HFrEF patients versus…
-
Media Release /
-
Media Release /- Secukinumab met primary endpoints demonstrating statistically significant improvements versus placebo in signs and symptoms of active psoriatic arthritis (PsA) in two pivotal Phase III studies-…
-
Media Release /
-
Media Release /- Secukinumab is the first selective IL-17A inhibitor to significantly improve signs and symptoms of ankylosing spondylitis (AS) versus placebo in Phase III studies- Exploratory analyses showed…
-
Media Release /
-
Media Release /- Four pivotal Phase III studies of secukinumab in psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to be presented for the first time at ACR 2014- Secukinumab is the first selective…
-
Media Release /
-
Media Release /Through music and resources Our Voice in Song™ inspires people living with relapsing MS to become more active managers of their diseaseInitiative launches with nationwide release of "I Can Do This,"…
